Stephens Has Lowered Expectations for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its target price decreased by Stephens from $15.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Stephens’ price target would indicate a potential upside of 39.86% from the company’s current price.

Several other equities research analysts have also recently commented on CERT. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research note on Monday, December 8th. Rothschild Redb upgraded shares of Certara to a “strong-buy” rating in a research note on Friday, November 21st. Barclays reduced their price objective on shares of Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. BMO Capital Markets assumed coverage on shares of Certara in a research report on Thursday, November 13th. They set a “market perform” rating and a $9.00 target price on the stock. Finally, Craig Hallum initiated coverage on Certara in a report on Monday, September 29th. They set a “buy” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.36.

Certara Stock Down 2.6%

CERT stock opened at $8.58 on Friday. The company has a 50 day moving average of $10.44 and a two-hundred day moving average of $10.87. The company has a market cap of $1.37 billion, a price-to-earnings ratio of 122.57 and a beta of 1.46. Certara has a 12-month low of $8.02 and a 12-month high of $15.69. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The business had revenue of $104.62 million during the quarter, compared to analyst estimates of $104.53 million. During the same period last year, the company earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Certara

Several large investors have recently made changes to their positions in the business. AdvisorNet Financial Inc bought a new stake in shares of Certara in the second quarter valued at approximately $25,000. First Horizon Corp bought a new stake in Certara in the 3rd quarter valued at $30,000. Versant Capital Management Inc grew its position in Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Certara during the 1st quarter worth about $31,000. Finally, Osaic Holdings Inc. increased its holdings in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.